Gilead Sciences offers steady dividend growth with a 2.99% yield. Read why the analyst nonetheless has a neutral rating on ...

Recent health news highlights financial and strategic developments in major pharmaceutical companies like Gilead and Merck, ...

Gilead Sciences reports profits but mixed revenue; Merck is in talks to acquire SpringWorks for $3.5 billion; measles cases ...

Nina Trentmann is the former bureau chief for The Wall Street Journal’s CFO Journal. Based in New York, Nina managed the ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...